Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947382 · ClinicalTrials.gov registry record
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
A clinical trial of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis, sponsored by Immunovia.
- Completed
- Registry status
- 1,066
- Enrollment target
- 15
- Study locations
NCT06947382: Completed study of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis, sponsored by Immunovia.
NCT06947382 is a study of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis that has completed, run by Immunovia. The registered enrollment target is 1,066 participants, below the 1,238-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (14% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06947382, a study of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis, has completed, sponsored by Immunovia.
- COMPLETED
- Registry status
- 1,066 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.
Conditions Studied
Study Locations (15)
California
- St. John's Cancer Institute - Burbank
- University of California San Diego - La Jolla
- Stanford Gastroenterology and Hepatology - Stanford
Other
- The Research Institute of the McGill University Health Centre - Montreal
- University of Verona - Verona
- Oslo University Hospital - Oslo
Virginia
- Inova Schar Cancer Institute - Fairfax
- Virginia Commonwealth University - Richmond
Arizona
- HonorHealth Clinical Research Institute - Scottsdale
Florida
- University of Miami - Miami
Illinois
- University of Chicago Medical Center - Chicago
New York
- Mount Sinai Hospital - New York
Oregon
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,066 participants |
| Start Date | 2024-09-02 |
| Est. Completion | 2025-01-06 |
What the finished NCT06947382 record still lists
NCT06947382 is an observational study that tracks outcomes without assigning an intervention. Its 1,066 participants enrollment target places it among the larger protocols in the corpus, below the 1,238-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (14% lower).
The record links to 4 conditions, with PDAC - Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06947382 lists 15 locations in 10 states (California, Other, Virginia).
Frequently Asked Questions
What is clinical trial NCT06947382 about?
NCT06947382 is a clinical study titled "Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer". This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to fa...
What is the current status of trial NCT06947382?
This trial is currently completed. The enrollment target is 1,066 participants. The study started on 2024-09-02. Estimated completion is 2025-01-06.
What conditions does trial NCT06947382 study?
This clinical trial studies the following conditions: PDAC - Pancreatic Ductal Adenocarcinoma, Cancer Diagnosis, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II.
Who is sponsoring clinical trial NCT06947382?
This trial is sponsored by Immunovia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947382 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PDAC - Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06947382's enrollment target sits among peer trials
1,066 3rd of 10 higher than 8 of 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PDAC - Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RECRUITING · Phase 1
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI